Phaseline

Targets › SLC18A2

SLC18A2 (Synaptic vesicular amine transporter): drug programs, companies and trials

5 programs from 5 companies in 7 trials: 5 Phase 2, 2 Phase 4; Neurology, Psychiatry, Metabolic and endocrine; next expected readout Jun 2027.

Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, Q05940)

Open in Phaseline: the race on SLC18A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospitals Cleveland Medical CenterDeutetrabenazine
Synaptic vesicular amine transporter inhibitor
SLC18A2Phase 4Tardive DyskinesiaOct 2027
Neurocrine BiosciencesValbenazine
Synaptic vesicular amine transporter inhibitor
SLC18A2Phase 4Schizophrenia; Trichotillomania (Hair-Pulling Disorder); Cervical DystoniaJun 2028
Vanderbilt University Medical CenterDeutetrabenazine
Synaptic vesicular amine transporter inhibitor
SLC18A2Phase 2Huntington DiseaseJun 2027
Medical University of LodzLisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Attention Deficit Disorder with HyperactivityDec 2027
Centre hospitalier de l'Université de Montréal (CHUM)Lisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Methamphetamine AbuseDec 2027

Conditions

Schizophrenia (1) Trichotillomania (Hair-Pulling Disorder) (1) Cervical Dystonia (1) Huntington Disease (1) Attention Deficit Disorder with Hyperactivity (1) Tardive Dyskinesia (1) Methamphetamine Abuse (1)

Modalities

small molecule (5)

Companies

Neurocrine Biosciences (1) Vanderbilt University Medical Center (1) Medical University of Lodz (1) University Hospitals Cleveland Medical Center (1) Centre hospitalier de l'Université de Montréal (CHUM) (1)

Related targets

SLC6A3 (2) SLC6A2 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.